Equities Analysts Set Expectations for RDY FY2025 Earnings

Dr. Reddy's Laboratories Limited (NYSE:RDY - Free Report) - Equities research analysts at Zacks Research raised their FY2025 earnings per share estimates for shares of Dr. Reddy's Laboratories in a research note issued to investors on Tuesday, November 26th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $0.81 for the year, up from their prior estimate of $0.80. The consensus estimate for Dr. Reddy's Laboratories' current full-year earnings is $0.83 per share. Zacks Research also issued estimates for Dr. Reddy's Laboratories' Q4 2025 earnings at $0.23 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.21 EPS, Q3 2026 earnings at $0.21 EPS, Q4 2026 earnings at $0.22 EPS, FY2026 earnings at $0.84 EPS, Q1 2027 earnings at $0.18 EPS and Q2 2027 earnings at $0.16 EPS.

Several other equities research analysts also recently weighed in on RDY. Barclays decreased their target price on Dr. Reddy's Laboratories from $17.40 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 6th. StockNews.com downgraded shares of Dr. Reddy's Laboratories from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, November 13th.

Dr. Reddy's Laboratories Trading Down 0.4 %

Shares of Dr. Reddy's Laboratories stock traded down $0.06 during trading hours on Thursday, reaching $14.08. The stock had a trading volume of 2,124,959 shares, compared to its average volume of 1,053,412. The firm has a market capitalization of $11.75 billion, a price-to-earnings ratio of 22.49 and a beta of 0.56. Dr. Reddy's Laboratories has a 1 year low of $12.90 and a 1 year high of $16.89. The company has a current ratio of 1.92, a quick ratio of 1.36 and a debt-to-equity ratio of 0.02. The firm has a 50 day simple moving average of $15.24 and a two-hundred day simple moving average of $15.33.

Institutional Trading of Dr. Reddy's Laboratories

Several large investors have recently modified their holdings of the business. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Dr. Reddy's Laboratories by 318.0% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company's stock valued at $28,411,000 after purchasing an additional 283,700 shares during the last quarter. Fisher Asset Management LLC boosted its stake in shares of Dr. Reddy's Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company's stock valued at $39,034,000 after buying an additional 183,146 shares during the last quarter. Millennium Management LLC grew its position in shares of Dr. Reddy's Laboratories by 61.4% during the second quarter. Millennium Management LLC now owns 332,502 shares of the company's stock worth $25,333,000 after buying an additional 126,472 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Dr. Reddy's Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company's stock worth $76,455,000 after buying an additional 114,294 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in Dr. Reddy's Laboratories by 2,197.8% in the first quarter. Jane Street Group LLC now owns 113,168 shares of the company's stock valued at $8,301,000 after acquiring an additional 108,243 shares in the last quarter. 14.02% of the stock is currently owned by institutional investors and hedge funds.

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.